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ABSTRACT
Background Linear immunoglobulin A bullous dermatosis (LABD) is a rare autoim-
mune subepidermal bullous disease. It is defined by continuous linear deposition of 
IgA in the basement membrane zone on direct immunofluorescence microscopy. The 
clinical presentations of LABD may mimic other diseases, and data in Taiwanese popu-
lations are still lacking. The current study aims to examine LABD status in Taiwan.
Methods We reviewed the database at our institute from 1995 to 2008. The gold stan-
dard for the diagnosis of LABD is based on continuous linear depositions of IgA in the 
basement membrane zone on direct immunofluorescence.
Results A total of 16 LABD patients were identified. Mean age at diagnosis was 
55 years, and most (> 80%) occurred after the fourth decade. The trunk was most com-
monly involved (76%). However, in contrast to previous reports, the mucosal involve-
ment was rare in our series (18%). Initial impressions were dermatitis herpetiformis in 
8 patients (50%), bullous pemphigoid in 4 patients (25%), and vasculitis, varicella, and 
pemphigus vulgaris in the remaining 4 patients (25%). Four patients reported a history 
of drug ingestion shortly before the onset of the disease, and all recovered after discon-
tinuing the offending drugs. One of them had griseofulvin-associated LABD, a case not 
reported previously. The other three drugs were rifampin, vancomycin and gemcitabine. 
Among the various regimens, dapsone (100 mg) twice a day achieved the best treatment 
response in the five treated patients.
Conclusion The rare and diverse presentations of LABD highlight the importance of our 
study results in aiding clinical diagnosis and planning treatment strategies.
Copyright © 2010, Taiwanese Dermatological Association. 
Published by Elsevier Taiwan LLC. All rights reserved.
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Introduction
Linear IgA bullous dermatosis (LABD) is a rare autoimmune 
subepidermal blistering disorder defined by the presence of 
homogenous linear deposits of IgA in the cutaneous base-
ment membrane zone (BMZ). LABD was first discussed in 
1901, with the description of 15 children having nonpruritic 
blistering eruptions.1,2 However, it was not recognized as an 
entity separate from dermatitis herpetiformis until 1979, based 
on the findings of immunopathology, and the lack of con-
sistent association with a gluten-sensitive enteropathy.2
The clinical manifestations of LABD are heterogeneous. 
Patients may have some features similar to both DH and 
bullous pemphigoid.2–4 Thus, it is difficult for clinicians to 
make the diagnosis of LABD with confidence. The causes 
of LABD are not clear. Certain drugs, autoimmune diseases, 
infection, chronic renal insufficiency and malignancies have 
all been reported to be associated with this disease.2–4 Since 
LABD is such a rare disease with diverse clinical manifesta-
tions and etiologies, reviewing our local data is crucial to 
providing clinicians with useful diagnostic clues. Here, we 
performed a retrospective analysis and collected cases of 
direct immunofluorescence (DIF)-proven LABD from our 
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institutional database to define the clinical features, patho-
logical findings, potential etiologies, treatment responses 
and clinical outcomes in a Taiwanese population.
Materials and methods
From 1995 to 2008, a total of 16 patients were identified 
from our institutional database. The gold standard for the 
diagnosis of LABD is based on the DIF of perilesional skin, 
which reveals continuous linear depositions of IgA in the 
BMZ. Medical records were reviewed to obtain informa-
tion on gender, age and location at onset, interval between 
disease onset and diagnosis confirmation, clinical manifes-
tations, symptoms, drug associations, underlying systemic 
diseases, preceding infections and treatment responses. 
“Drug association” was defined as new drug intake identi-
fied by history from 1 to 14 days before the eruption onset. 
“Effective treatment” was defined as no new blister forma-
tion and healing of old lesions during tapering of medica-
tion. If disease activity increased once medications were 
tapered, but could still be controlled after resuming the 
previous dosage, the response to treatment was defined as 
“stationary”. Continuous progression in disease severity in 
spite of persistent medical treatment was regarded as “inef-
fective” treatment response. “Remission” was defined as no 
relapse of the disease after complete discontinuation of the 
medications. Clinical follow-up outcomes were assessed at 
clinic visits and/or by telephone interviews for those who 
couldn’t come to our clinic due to living a long distance 
from the clinic or remission of the disease.
Results
Patient characteristics
Demographic data are presented in Figure 1 and Table 1. 
Of the 16 patients, 8 were males (50%). There was no gen-
der difference in our patient cohort. The mean age at diag-
nosis was 55 years (median, 57 years; range, 24–80 years). 
Figure 1 Age distribution of disease onset.
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Table 1 Clinical and immunopathological data of the 16 cases.
Patient
  Clinical feature Immunopathology
 
Sex
 Age at Mucosal Interval between Histopathology 
IgA
 
IgG
 
C3
 Treatment/responseno.
  onset (yr) lesion onset and diagnosis (d)
 1 M 68 – 20 SE bullae/PMN/Eos + – –  DC gemcitabine + low 
dose prednisolone/R
 2 M 35 – 19 SE bullae/PMN  + + (weak)  +  Dapsone/E
 3 M 58 + 7 SE bullae/Eos + – – DC vancomycin/R
 4 M 60 – 9 SE bullae/PMN + – – Dapsone/E
 5 F 31 – 3 SE bullae/PMN + + (weak) – Dapsone/E
 6 M 80 + 292 SE bullae/PMN + – –  Systemic antibiotics 
with prednisolone/R 
 7 F 24 – 2 SE bullae/PMN + – – Topical/lost to FU
 8 M 34 – 18 Superficial lymphocytic + – – SR
     vasculitis
 9 M 79 – 25 SE bullae/PMN + – – Dapsone/E
10 F 64 – 20 SE bullae/PMN/Eos + + (weak) + Prednisolone/lost to FU
11 F 66 + 51 SE bullae/Eos + – – Prednisolone/E
12 M 53 – 339 SE bullae/PMN + + (weak) + Dapsone/E
13 F 73 – 25 SE bullae/Eos + – + Prednisolone/E
14 F 57 – NA SE bullae/PMN + (strong) + +  Prednisolone and 
Hydroxychloroquine/S
15 F 42 – 10 SE bullae/PMN + – – DC griseofulvin
16 M 65 – 26 SE bullae/PMN + – – DC rifampin
M = male; F = female; NA = not available; SE = subepidermal; PMN = polymorphonuclear neutrophils; Eos = eosinophils; DC = discontinued; R = remission; 
E = effective; S = stationary; SR = spontaneous remission; FU = follow-up.
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patients, and the remaining patient presented with vasculitis-
like lesions.
Fourteen (90%) patients complained of pruritus before the 
onset of eruptions or during the occurrence of eruptions. 
There were no concurrent constitutional symptoms, such as 
fever, arthralgia or muscle weakness. In our series, mucous 
Most patients (> 80%) had LABD after the fourth decade of 
life. The interval between disease onset and diagnosis con-
firmation by DIF varied. The mean interval was 58 days, how-
ever, two patients had an extremely long period before 
accurate diagnosis was made. One patient (No. 12) had been 
diagnosed as generalized eczema until she was referred to 
our institute, where a biopsy with DIF was performed. Several 
biopsies were performed on one patient (No. 6) until the 
confirmation of the diagnosis was made.
Clinical manifestations
The distribution of the eruptions is shown in Figure 2. The 
trunk was involved in 12 (76%) patients, the extremities in 
10 (62%) and perineum in 2 patients (12%). Eight (50%) pa-
tients presented with a combination of annular or grouped 
papules, vesicles, and bullae. Thus, the initial impression of 
the symptoms of these eight patients was a diagnosis of der-
matitis herpetiformis (Figure 3). Four patients (25%) presented 
with tense and large blisters on the erythematous base, and 
hence were initially diagnosed with bullous pemphigoid. 
Pemphigus vulgaris-like lesions were noted in three of these 
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Figure 2 Distribution of the involved areas.
Figure 3 (A) Clinical pictures of patient No. 15. Symmetrically grouped erythematous papules, vesicles and bullae arranged in an annular pattern 
on the upper chest, which is similar to the presentation of dermatitis herpetiformis. (B) Vesicles and blisters superimposed at the edge of annular 
lesions, creating a typical “string of beads” sign. (C) Clinical pictures of patient No. 10. Erythematous, slightly edematous plaques studded with 
large, tense bullae on the lateral aspect of trunk which is easily misdiagnosed as bullous pemphigoid. (D) Classical “clusters of jewels” appear-
ance: cluster tense blisters on the erythematous base.
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C D
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after the administration of systemic antibiotics and low dose 
prednisolone. In the remaining eight patients, prednisolone 
was used as the initial medication in two patients, resulting 
in a good response. Dapsone was used in the other six pa-
tients with five responding excellently to medical treatment, 
and with one patient having an adverse effect (dapsone hy-
persensitivity syndrome). The treatment was then shifted to 
prednisolone and combination therapy with hydroxychloro-
quine to control the disease activity.
Discussion
In the present study, we retrospectively reviewed the clini-
cal and pathological features of DIF-proven LABD in a 
Taiwanese population. We found a low incidence of mu-
cosal involvement as well as fair recovery after discontinu-
ing the offending medication in drug-related LABD. The 
rare and diverse presentation of this disease highlights the 
membrane with the presence of erosion on the lips and/or 
buccal mucosa occurred in only 3 patients (18%).
Association with drugs and systemic diseases
Four patients (25%) reported a history of drug ingestion 
shortly before the onset of the disease, including rifampin, 
vancomycin, gemcitabine, and griseofulvin. One had a re-
current urinary tract infection before each episode of LABD. 
Three patients had chronic renal insufficiency before the 
onset of LABD.
Histopathology and immunopathology
A total of 19 tissue specimens from the 16 patients were 
reviewed. Subepidermal blisters were seen in 15 patients; 
polymorphonuclear neutrophil infiltration in the upper der-
mis predominated in 12 patients; both polymorphonuclear 
neutrophil and eosinophil infiltrations were observed in 
three patients, and mainly eosinophil infiltration in two 
patients (Figure 4).
The immunopathological findings are summarized in 
Table 1. In 10 patients (62.5%), IgA was the only positive 
immunoreactant (Figure 5), while in the remaining 6 patients, 
IgG or C3 were also weakly positive in addition to IgA.
Treatment and clinical response
Medications and treatment responses are summarized in 
Table 1. Treatment responses were not available in two pa-
tients who were lost to follow-up. Spontaneous remission 
without any treatment was noted in one patient. In the four 
patients with drug-associated LABD, all eruptions resolved 
completely after discontinuing the offending drugs with 
(n = 1, prednisolone 0.5–1 mg/kg/day) or without (n = 3) con-
current use of systemic medications. In the patient with uri-
nary tract infection-related LABD, the eruptions subsided 
Figure 4 Histopathology of skin biopsy on the upper chest lesion from patient No. 15. (A) A subepidermal blister with intact epidermis (H&E, 
20×). (B) Prominent neutrophils with few eosinophils in the dermal papillary tips (H&E, 200×).
A B
Figure 5 Direct immunofluorescence microscopy performed on the 
perilesional skin biopsy specimen (200×). Continuous linear IgA depo-
sition in the basement membrane zone was noted.
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also be indistinguishable from bullous pemphigoid. These 
pathological findings were all observed in our series. For an 
accurate diagnosis, DIF is considered as the gold standard 
diagnostic modality.10 The occurrence of continuous linear 
IgA deposition in the BMZ is a specific finding in LABD, 
while a papillary granular IgA deposition is suggestive of 
dermatitis herpetiformis; continuous linear IgG deposition 
in the BMZ is typical in bullous pemphigoid.9,10 Although a 
linear distribution of BMZ-specific IgA antibodies on DIF is 
the gold standard for diagnosis of LABD, other immunologi-
cal factors can also be involved in LABD.2,10 In our study, five 
patients showed depositions of IgG antibodies in addition 
to IgA antibodies on DIF. Chan et al10 suggested that LABD 
and bullous pemphigoid can usually be separated based on 
the greater fluorescence intensity of one of the antibodies, 
either IgG or IgA, in combination with clinical and immun-
opathologic features. In the four patients whose immunos-
taining showed a presence of both IgA and IgG antibodies, 
all had a greater fluorescence intensity for IgA antibody. It 
has been proposed that the deposition of IgA antibody 
might lead to neutrophil chemotaxis and complement acti-
vation with eventual loss of adhesion at the dermal-epidermal 
junction and subepidermal blister formation.2
A subset of patients has been described with drug-
induced LABD.11–13 Intravenous vancomycin is the most 
common offending drug.13 While its mechanism is still un-
clear, it has been proposed that drug-specific T cells may 
release Th2 cytokines such as interleukin IL-4, IL-5, IL-6, 
IL-10 and transforming growth factor-β which would then 
stimulate the production of IgA antibodies.12,14 The impor-
tance of drugs as the causative agent for LABD lies in that 
the eruptions resolve completely upon discontinuation of 
the offending drugs.11,12 Therefore, a detailed medication 
history is crucial in the diagnosis and treatment of LABD. 
In our study, four patients had drug-related LABD, and all 
experienced fair recovery after withdrawal of the offending 
medications. Of particular note is that one case was related 
to griseofulvin, which has not been reported previously to 
be associated with LABD.
Traditionally, the treatment of choice for LABD is dap-
sone.2,9 Treatment responses in our patients also supported 
this previous experience since all patients who received dap-
sone had excellent recovery except for one with adverse 
Table 2 Comparisons of epidemiological and clinical data in three 
series of linear immunoglobulin A bullous dermatosis.3,6
 Our series Leonard et al3 Weng et al6
Time 1995–2008 NA 1987–1991
Case number 16 34 17
Male-to-female ratio 1:1 1:1.6 2.4:1
Mean age 55 45 47
Mucosal involvement 3/16 (18%) NA 8/17 (47%)
NA = not available.
importance of our study results in aiding clinical diagnosis 
and planning treatment strategies.
Although the incidence of LABD varies in different pub-
lished reports, it is certainly a rare disease worldwide. The 
estimated incidence is 0.26, 0.52 and 0.22 per million 
populations per year in Singapore, France and Germany, 
repectively.5 To the best of our knowledge, there is no pre-
vious report of incidence of bullous diseases in Taiwan. 
A calculation of all cases receiving DIF examinations during 
the same study period revealed that there were 226 cases 
of bullous pemphigoid, 91 cases of pemphigus (including 
pemphigus vulgaris and pemphigus foliaceus), while only 
16 cases of LABD confirmed by DIF examinations. Comparing 
with previous reports from Germany and France,6,7 the inci-
dences of pemphigus were around 0.98–1.7 cases per mil-
lion inhabitants per year, while the incidences of LABD were 
0.22–0.52 cases per million inhabitants per year. Therefore, 
the relative incidences between LABD and pemphigus were 
around 0.22–0.34 fold in Germany and France. In our hos-
pital, the relative case numbers of LABD and pemphigus 
(16 vs. 91, 0.18 fold) during the study period were similar 
to that of previous reports, indicating that LABD is also a 
rare disease in Taiwan. The lack of racial difference in dis-
ease incidence suggests that extrinsic factors such as drugs 
and systemic illness play much more important roles in the 
etiology of LABD than do ethnic and genetic considerations.
Comparisons of epidemiological and clinical data re-
ported by Weng et al,8 Leonard et al3 and our present study 
are summarized in Table 2. Gender difference was not sig-
nificant in our series. However, Weng et al8 reported a male 
predominance (2.4:1), while a slight predominance of fe-
males was observed by Leonard et al (1:1.6).3 Although the 
mean age of disease onset was relatively older in our series, 
most of our patients were older than 40 years, in line with 
previous reports.2,3 Similar to other series,2–4 cutaneous 
manifestation was also heterogeneous in our study (8 with 
dermatitis herpetiformis-like skin lesions, 4 with bullous 
pemphigoid-like lesions, 2 with pemphigus vulgaris-like le-
sions, 1 with a varicella-like lesion and 1 with a vasculitis-
like lesion). Therefore, LABD should be considered as a 
potential diagnosis in patients presenting with blisters in an 
annular distribution. Pruritus before or during the disease 
course was also a common finding both in our patients and 
previous series.2,4,9 However, mucous membrane involve-
ment occurred only in 3 patients (18%) in our study, while 
studies by Weng et al8 and Guide and Marinkovich2 dem-
onstrated a much higher proportion of mucosal involvement 
(47% and 80%, respectively). The low incidence of mu-
cosal involvement is probably a unique feature in Taiwanese 
patients with LABD.
Similar to dermatitis herpetiformis, the histopathology 
of LABD reveals subepidermal bullae with a superficial 
dermal neutrophilic infiltration.2,3,9 Occasionally, there are 
eosinophils mixed with neutrophils, and thus LABD can 
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effect. Dapsone should be prescribed with caution because 
of its complications.9 The most common adverse effect is 
hemolytic anemia, which can be severe in patients with 
glucose-6-phosphate dehydrogenase deficiency.9 Potentially 
fatal side effects include hepatotoxicity and dapsone hyper-
sensitivity syndrome, which often occur within the first 3 
months. Important measures to prevent these adverse ef-
fects include checking a baseline complete blood count, 
liver enzymes, and glucose-6-phosphate dehydrogenase 
levels before and during the administration of dapsone. Al-
ternative medications such as sulfapyridine, corticosteroid, 
colchicine, tetracycline and nicotinamide, have also been 
reported to be beneficial for LABD treatment.2,9
Since this study is based on a retrospective chart review 
with some clinical follow-up data obtained by telephone 
interview, treatment strategies may change over time and 
there may be bias from interviewers and patients. In addi-
tion, the case number was limited. Further multicenter col-
laborations to establish our local database may be needed 
to confirm results from our present study.
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